We are experts in developing novel sub-unit vaccines
Our initial focus is on animal health. We aim to capitalize on the first approval of a CrisBio® - based vaccine dossier (expected in 2020) to expand into human health and thereby fully exploit the platform’s potential. CrisBio® also has applications in the Diagnostics sector, where it is already being exploited by a commercial partner.
Our current portfolio comprises 6 vaccines across livestock species.
Proof of concepts have been generated in > 20 additional vaccine antigens
Value through collaborations
Our go to market strategy is inherently linked to collaborations. We offer:
• Development of tailor-made baculovirus vectors optimized for industrial production.
• Proof-of-concept studies to validate the production of recombinant proteins in CrisBio®.
• Supply of recombinant proteins produced in CrisBio® through license agreements.
• Development of proprietary portfolios.
Algenex is led by an internationally experienced management team, that is supported by a well-balanced Strategic Advisory Board that combines industry and investment experience.
Company Details
- Employees
- 42
- Founded
- -
- Address
- Ronda De Poniente, 14, Tres Cantos,comunidad De Madrid 28760,spain
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- algenex.es
- HQ
- Tres Cantos, Comunidad de Madrid
Algenex S.l Questions
Algenex S.L's website is algenex.es
Algenex S.L's LinkedIn profile is https://es.linkedin.com/company/algenex-s.l
Algenex S.L has
42 employees.
View email and phone details for 42
employees at Algenex S.L.
Algenex S.L's industry is
Biotechnology Research
Algenex S.L's top competitors are
Cocoon Bioscience,
Sylentis,
Vivia Biotech,
Laboratorios Normon,
Amadix,
Aitenea Biotech,
Liof Pharma,
Cocoon,
Pharmamar,
Suri Biotech.
Algenex S.L's categories are Biotechnology Research
Algenex S.L's founding year is 2005
